海正藥業(600267.SH):導明醫藥(香港)已將交易尾款直接支付至公司指定賬户
格隆匯1月10日丨海正藥業(600267.SH)披露轉讓參股公司浙江導明醫藥科技有限公司20.24%股權的進展,公司於2019年5月28日召開的第八屆董事會第二次會議審議通過了《關於轉讓浙江導明醫藥科技有限公司20.24%股權的議案》。2019年5月31日,公司在台州市產權交易所有限公司(“台交所”)公開掛牌轉讓參股公司浙江導明醫藥科技有限公司(“導明醫藥(浙江)”)20.24%股權,並由台交所組織實施交易。2019年10月29日,DTRM Biopharma (Hong Kong)Limited(“導明醫藥(香港)”)成功摘牌,摘牌價格為14168萬元人民幣或等值美元,並且與公司完成《浙江導明醫藥科技有限公司20.24%國有股權轉讓合同》的簽署。
鑑於資產交割的相關手續較之前預計程度更為複雜,如存在中國大陸、中國香港、開曼羣島等不同法律體系等原因,雙方預計交割完成日期較原計劃的2019年11月29日將有所推遲。2019年11月29日,公司與導明醫藥(香港)簽訂了《浙江導明醫藥科技有限公司20.24%國有股權轉讓合同之補充合同》,約定導明醫藥(香港)向公司的尾款支付不得晚於2020年1月10日。
2020年1月10日,導明醫藥(香港)已將此次交易尾款12668萬元人民幣或等值美元直接支付至公司指定的銀行賬户,加導明醫藥(香港)前期已支付的競買保證金1500萬元人民幣,此次股權轉讓款已全額到賬。
此次公司轉讓導明醫藥(浙江)20.24%收到的股權轉讓款大於對應股權賬面價值5688萬元,由於公司前次轉讓導明醫藥(浙江)33.36%股權形成的對賭條款仍處於對賭期,基於該項潛在的回購義務此次轉讓收益暫不確認。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.